Interactive medical device QMS training with scenario-based questions and gamified learning
Reference answers maintained by SKY Biotechnology, a CE marked and ISO 13485 certified medical device manufacturer in Pendik, Istanbul, Turkiye. Provided for information and does not constitute regulatory advice.
ISO 13485:2016 deliberately does not adopt the High Level Structure of ISO 9001, and replaces its continual improvement emphasis with an emphasis on sustained regulatory compliance. The substantive differences are: Clause 4.2.3 requires a Medical Device File for each device type or family, referencing all evidence from design through post-market activities; Clause 7.3 mandates design and development controls, with design transfer and design verification and validation treated as separately documented activities; Clause 7.5.6 requires validation of special processes whose output cannot be verified by subsequent monitoring, such as sterilisation, cleanroom assembly and welding; Clauses 7.5.8 and 7.5.9 impose traceability aligned with UDI, including batch or serial level records for implantable devices; and Clauses 8.2.1 and 8.2.2 require feedback, complaint handling and vigilance reporting to be integrated into the quality system. Where ISO 9001 targets customer satisfaction, ISO 13485 targets a safe and performing device.
No. ISO 13485:2016 provides the structural basis for the quality management system required by MDR Article 10(9), but it is not equivalent to MDR. As a harmonised standard, EN ISO 13485:2016 with amendment A11:2021 maps the gaps between MDR and the ISO text through Annex ZA. Even so, MDR imposes obligations beyond ISO 13485: appointment of a Person Responsible for Regulatory Compliance under Article 15; clinical evaluation under Article 61 and Annex XIV Part A, with clinical investigation where required; a post-market surveillance plan and PSUR under Articles 83 to 86, and vigilance reporting under Articles 87 to 90; a PMCF plan and evaluation report under Article 84 and Annex XIV Part B; and a risk management system aligned with ISO 14971:2019 under Annex I Chapter 3, in which the acceptability of residual risk is justified through benefit-risk analysis. In practice, even a manufacturer holding an ISO 13485 certificate must additionally be assessed by a Notified Body under MDR Annex IX, or Annex X combined with Annex XI, for all devices in Class IIa and above.
Under Clause 7.5.6 sterilisation is a special process: terminal sterility cannot be verified by testing every batch, so process reproducibility must be demonstrated in advance. For gamma irradiation, ISO 11137 parts 1 and 2 require bioburden determination and a dose setting study using VDmax25 or Method 1; the target sterility assurance level is typically 10 to the minus 6, with quarterly dose audits sustained across at least three consecutive production batches. ISO 11135 applies to ethylene oxide and ISO 17665 to moist heat, both requiring documented IQ, OQ and PQ and a half-cycle approach. Cleanroom manufacturing is qualified to ISO 14644-1 classification, typically ISO Class 7 or 8, with records for particle counts, air change rate, pressure cascade, recovery time and environmental microbiological monitoring, each with trend analysis. On the packaging side ISO 11607 parts 1 and 2 govern validation of the sterile barrier system and the sealing process, with shelf life supported by accelerated and real-time ageing. The records most frequently requested at audit are the validation master plan, IQ, OQ and PQ protocols and reports, bioburden and dose audit reports, ISO 10993-7 ethylene oxide residual analyses, equipment calibration records, personnel training and aseptic gowning qualification records, and the revalidation justification file.